EXELIXIS INC
For the period ended Mar 29, 2024. Filed Apr 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 29, 2024 · Filed Apr 30, 2024
EXEL$70.58-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net income | $37,317 | $40,028 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation | 6,378 | 6,855 |
| Stock-based compensation | 19,113 | 16,661 |
| Non-cash lease expense | 6,764 | 6,731 |
| Acquired in-process research and development technology | 19,500 | 36,500 |
| Other, net | 9,206 | (3,743) |
| Changes in operating assets and liabilities: | ||
| Trade receivables, net | (3,170) | (19,178) |
| Inventory | 1,715 | (8,370) |
| Prepaid expenses and other assets | 10,075 | 10,372 |
| Accrued collaboration liabilities | (3,829) | (1,864) |
| Accounts payable and other liabilities | (34,247) | 416 |
| Net cash provided by operating activities | 68,822 | 84,408 |
| Cash flows from investing activities: | ||
| Purchases of property, equipment and other, net | (9,691) | (12,024) |
| Acquired in-process research and development technology | (8,500) | (36,500) |
| Purchases of investments | (138,468) | (311,837) |
| Proceeds from maturities and sales of investments | 268,452 | 310,769 |
| Net cash provided by (used in) investing activities | 111,793 | (49,592) |
| Cash flows from financing activities: | ||
| Payments for repurchases of common stock | (185,375) | — |
| Proceeds from issuance of common stock under equity incentive plans | 8,315 | 7,143 |
| Taxes paid related to net share settlement of equity awards | (6,988) | (2,557) |
| Net cash provided by (used in) financing activities | (184,048) | 4,586 |
| Net increase (decrease) in cash and cash equivalents | (3,433) | 39,402 |
| Cash and cash equivalents at beginning of period | 262,994 | 502,677 |
| Cash and cash equivalents at end of period | $259,561 | $542,079 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.